UQ-led teams to develop advanced cattle vaccines
19 July, 2012 by Dylan Bushell-EmblingTwo University of Queensland scientists are leading teams to develop cutting-edge vaccines aimed at fighting cattle tick infestation and common bovine diseases.
Top performing biotechs delivered over 100% returns in FY12
19 July, 2012 by Dylan Bushell-EmblingThe three top performing life science stocks over the last four quarters delivered more than 100% returns over that time.
Sirtex study to pave way for wider use of SIR-Spheres
19 July, 2012 by Dylan Bushell-EmblingA large-scale trial could pave the way for wider adoption of Sirtex Medical's (ASX:SRX) SIR-Spheres in first-line oncology therapy.
Commercialisation Australia to provide more support for manufacturing
19 July, 2012 by AusBiotechNew funding guidelines, foreshadowed in December, deliver more generous arrangements for early stage commercialisation (ESC) grant recipients needing to establish manufacturing facilities in Australia to fully commercialise their invention.
Bioshares summit to discuss bypassing big pharma
17 July, 2012 by Dylan Bushell-EmblingA central theme of this week's Bioshares Biotech Summit in New Zealand is the trend of foregoing outlicensing to big pharma in order to bring products to market alone or with a smaller partner.
GI Dynamics extends reach of diabetes treatment
17 July, 2012 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) has expanded the reach of its EndoBarrier diabetes treatment to France and to more clinics in its existing markets.
Biotechs undo gains from last quarter
17 July, 2012 by Tim DeanMany Australian biotech stocks have seen a reversal of fortune in the most recent quarter, with market volatility and some disappointing results hampering share prices.
Student volunteer program and excellence awards closing soon
17 July, 2012 by AusBiotechTwo of AusBiotech’s most important student programs to assist bio-students’ linkages with industry are closing soon for 2012.
Recombined virus from vaccines poses no threat to humans
13 July, 2012 by Tim DeanTwo live attenuated vaccines in poultry have recombined to produce a new virulent herpesvirus, although the probability of a similar event in human viruses is vanishingly remote, say scientists.
Movers and Shakers
12 July, 2012 by Dylan Bushell-EmblingAgenix business advisor; AusBiotech board member; Director for new La Trobe institute; OBodies advisory board; Mesoblast director; AHG board switch-up.
Draft NSW Manufacturing Industry Action Plan open for comment
10 July, 2012 by AusBiotechThe NSW Government has published its draft Manufacturing Industry Action Plan and has invited comment on the plan.
GTG ramps up gene patent litigation efforts
10 July, 2012 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) has cemented its relationship with its intellectual property bulldog, Sheridan Ross, as it seeks to assert its DNA patents in markets outside of the US.
MDI, CSIRO team to cut Penthrox production costs
10 July, 2012 by Dylan Bushell-EmblingThe CSIRO will help MDI improve the production process for homegrown analgesic Penthrox to support the company's EU expansion plans for the product.
Immuron to issue $4.1m worth of options
09 July, 2012 by Dylan Bushell-EmblingImmuron (ASX:IMC) plans to issue $4.1m worth of options exercisable at $0.04 per share - just under twice the current trading price of the company's shares.
Latest AusBiotech journal features special investment edition
05 July, 2012 by AusBiotechAusBiotech is pleased to announce that the July edition of AusBiotech’s journal, Australasian Biotechnology, is now published, featuring a special investment edition.
